Innovation Park recovers revenue you've already earned, builds the partnership systems that grow it, and installs the operating systems that keep it from leaking again — across healthcare, banking, and multi-location operators.
3× fee recovery guarantee on qualifying engagements · de-identified data, NDA before any exchange · runs in your browser, nothing to install.
"I cannot explain the flat referral line to my CFO. I need a board-defensible answer in 60 days. Not for $1.8M."
"I know my referral numbers are wrong. I need someone who has been inside this exact problem 200 times — not someone reading slides."
Most firms sell you one of these. We run all three as a loop — diagnose what's leaking, build the partnerships that grow the top line, then install the systems that hold the gains.
The Revenue Recovery Lens runs eight recovery patterns against your own de-identified data and ranks what's recoverable — payer underpayment, fee leakage, pricing variance, dormancy and more. Conservative by construction, with a realized-vs-estimate track record.
A standardized referral and partnership system — partner value propositions, synergy maps, BD team structure and compliance (Anti-Kickback, Stark, HIPAA) — built around a five-step process from strategy to expansion. Past and present customers alone are often 40%+ of referral volume.
Recovery that doesn't leak again. We stand up the operating layer — a private, in-tenant company “One Brain” that unifies your communications and data and runs a prompt battery surfacing structural risk and its dollar impact, plus the CRM, dashboards and reconciliation loop that keep value booked.
"Five to seven weekly client onboardings became 26 in a single month. The protocol Innovation Park built sits inside our coordinator workflow today — we did not buy software, we did not hire, the relationships we used were already in our network."
Revenue Lens is an AI-assisted scan of partnership and referral networks that finds dormant revenue relationships hidden inside aggregate metrics. Built from 1,000+ direct company audits. Median dormancy rate across the dataset: 34%. Top-to-bottom location variance inside a portfolio: typically 6–8×.
Inside a typical 12-location operator, the aggregate referral line looks stable while three locations are quietly carrying the entire portfolio. Site-to-site conversion variance is 3–6× on the same referrer base. A third of historically active partners haven't sent anything in 90+ days. The branch director sees their own numbers; the rollup hides the rest; the operating partner gets a number on a sheet with no way to interrogate it.
Revenue Lens surfaces the concentration risk before it shows up in revenue. The scan maps every revenue-generating relationship the operator has had, time-stamps the last active signal from each, ranks dormancy by recoverable value, and outputs a sequenced reactivation list. It is not a tool. It is a methodology refined across 200+ engagements that the AI layer now scales across a portfolio in days, not quarters.
34% of historically active partners sent zero in the last 90 days. The aggregate volume looked stable because new partners offset the dormancy — until they stopped.
Median dormancy · 34%At a 12-location oral surgery group, 18 GP referring practices were carrying the entire network. If any two of them paused, the revenue line collapses.
Top 15% of partners · ~70% of volumeInside the $72M senior living portfolio, top-to-bottom community conversion variance was 6.2× — same referrer base, same offering, very different operator behavior.
Community variance · 6.2×Post-acquisition SaaS partner programs running Crossbeam or PartnerStack consistently report a single attributed-revenue number diligence teams disqualify in 15 minutes. Partner-influenced vs partner-sourced is never enforced.
Diligence disqualification rate · > 60%Across PE healthcare portcos 12–24 months post-acquisition, 60%+ of pricing tiers have not been touched since close. Cost inflation has compressed the unit economics; the rollup hides it because volume is stable.
Untouched pricing tiers · 60%+Five questions, published sector benchmarks, and a conservative dollar figure for the dormant referral revenue inside your network. No email required.
Estimate only · calibrated against published sector benchmarks. For a named, board-ready figure, book a 30-minute qualification call.
30 minutes with a founder — Tyler or Julia. We confirm fit, scope, and timeline. If your portfolio doesn't fit, we say so on the call — and qualifying engagements carry a 3× fee recovery guarantee.
Two ICPs, one methodology. If you don't recognise yourself in one of them, we'll tell you on the qualification call. We say no more often than we say yes.
You sit at a healthcare-focused PE firm. One or more portfolio companies — home care, DSO, senior living, medspa, hospice — has a referral revenue line that's flat or declining, and the operator can't explain why. The value-creation clock is running. McKinsey quoted $1.8M and four months. You need a board-defensible answer in 60 days.
You run a multi-location home care agency, DSO, senior living group, medspa, or hospice between $5M and $150M revenue. You've tried a marketing coordinator, a new CRM, thank-you cards. Some sites are crushing it. Some are dead. You can't see where the dormancy is, you don't have $2M for McKinsey, and the people you've hired have never been inside a 12-location home care operation. You need someone who has — 200 times.
A mid-market PE fund engaged Innovation Park 18 months post-acquisition after referral revenue targets were being missed across the portfolio. The aggregate revenue line was stable. The fund had a Q3 board meeting in 90 days and no defensible explanation.
The Revenue Lens scan ingested the referral history, time-stamped every relationship, and produced the dormancy concentration map. Three findings surfaced: referral attribution was undocumented across all 40 communities; pricing had not been renegotiated since acquisition; and the three largest referral sources had gone dormant — silently — over the previous six months.
Total recoverable annual revenue identified across the portfolio: $72M. Per community: roughly $1.8M of additional ARR. No new marketing spend. No new headcount. The methodology surfaced the relationships and the operator behaviour gaps that had been there the entire time, hidden under a rollup that looked stable.
The CFO walked the next board meeting with a quantified recovery plan instead of a problem statement. That is the difference Revenue Lens produces, and that is what the diagnostic delivers in 60 days.
Belgium is Europe's fastest clinical trial approval market — 18–26 days versus the EU average of 60+. Home to imec (5,500 researchers, 600+ industry partners), EIT Health, and a tax architecture that combines the 3.75% Innovation Income Deduction on qualifying IP income, an 80% R&D payroll tax exemption, and a 100% Dividend Received Deduction at holding level. Innovation Park provides direct warm introductions into VLAIO, imec, EIT Health, and Horizon Europe — and integrates the tax-structuring pathway into the institutional sequence. Not broker introductions, existing relationships.
In 12 months working with Enlipsium — a non-EU radiotherapy device spinoff entering Europe — we helped Enlipsium establish 13 institutional relationships, $50M+ in estimated contract value, a €500K grant, and cancer-centre deployments through the VLAIO, imec, EIT Health, and clinical research network. Most companies wait 18 months for a first clinical meeting. The institutional sequence is the methodology — and it is not something you broker. You hold it because you've spent years building it.
Across 1,000+ companies audited, the same five leakage patterns surface in different shapes. These four are representative — named engagements have video testimonials on file; anonymous engagements are scope-confirmable under NDA.
Flat referral volume, dormant discharge-planner relationships, no attribution. The 72-hour signal protocol rebuilt the network. Weekly client onboarding moved from 5–7 to 26 in one month.
34% of historically active GP referrers had sent zero cases in 90+ days. 18 practices were carrying the entire network. The aggregate volume looked stable; the concentration risk was catastrophic.
Pricing un-updated 24 months across 60% of tiers. $340K in AR over 120 days from lapsed autopay. Zero tracked revenue from 80+ active referrers. Three gaps, one recovery system.
A device in a market where most companies wait 18 months for a first clinical meeting. 13 institutional relationships established, 3 contracts in active negotiation, €500K grant facilitated through VLAIO & imec.
For PE healthcare portcos under $250M EBITDA, the realistic shortlist is us, Accordion, and Cuesta Partners. McKinsey is the wrong tool at this scale and we won't pretend otherwise. A&M is the most dangerous comparator — their practitioner DNA is genuinely close to ours, but their economic floor sits above our price point. Here is the honest comparison.
If your portco has fewer than 50 locations or under $250M EBITDA, Accordion and Cuesta are your real comparators. We are built for the same buyer — with a tighter scope, a lower price point, and a benchmark they don't have.
We will tell you on the call which firm fits your portfolio best — including theirs. We say no more often than we say yes.
The 60-day diagnostic ends with a board-ready PDF, a 90-minute presentation, a dormancy map, and a sequenced reactivation list. For most engagements, that is where it should end — your team takes the playbook and runs it.
For roughly half of clients, the right second step is a monthly retainer that keeps the methodology operational: an AI scanning layer plugged into the partner / referral network, weekly intelligence on dormancy, monthly review, and a single phone number when concentration risk shifts. We call it AI Revenue System Integration. It is not consulting. It is the methodology running as an always-on system.
We are explicit about this so the diagnostic isn't a stealth sales call. If the recoverable revenue we surface doesn't justify ongoing work, we say so on the presentation call.
Our model. The engagement is recovery-aligned: a fixed-scope diagnostic plus a share of the revenue actually recovered through the engagement. Aligned incentives — we only fully win when you do. 3× fee recovery guarantee (Referral Partnership Revenue Recovery and Revenue Optimization engagements · $30M+ revenue): we recover at least three times our fee, or we keep working at no additional fee until we do. *Recovery share applies to revenue recovered in the 12 months following the diagnostic, attributable to interventions named in the report.
60 days · board-ready PDF · 90-min results presentation · 3-month implementation roadmap · SIGNAL Brief for 3 months
Always-on dormancy scanning · monthly review · concentration alerts · weekly opportunity brief · founder hours
Institutional access · regulatory mapping · partner matching · grant facilitation · co-engagement where applicable
Patterns from 1,000+ audits, weekly. No pitch, no marketing. Read by PE operating partners and healthcare operators.
Every engagement is led personally by Tyler or Julia — never delegated to a junior. Same methodology, different access surface. They have written and worked together since 2024.
Tyler built the Revenue Lens methodology from 1,000+ direct company audits — not from literature, and not from a conference room. 21 years inside healthcare operations, revenue architecture, and partnership systems. Verticals: home care, hospice, DSO, senior living, medspa.
Six years of building institutional relationships inside the Flemish innovation ecosystem — not to broker introductions, but to work directly alongside the institutions that matter. Featured in Forbes, Bloomberg, Global Finance, Microsoft Centre of Excellence, Mondaq. Head of Partnerships, AI in Defence Summit Brussels 2027 (EU Commissioner keynote).
Healthcare engagements operate under a mutual NDA before any data exchange, with a separate Business Associate Agreement (BAA) on request for any work that touches PHI. Most of our diagnostic work runs on de-identified pipeline and referral data — we do not require access to patient records for the core scan. Engagement letters specify data scope, retention, and deletion timeline line by line. Diligence-friendly for sponsor review.
In two active engagements this month (DSO and home health), the highest-volume referrer at each location was concentrated on a single weekday — Friday discharges, Friday case submissions. When the referring contact rotated off-shift in February, weekly volume dropped 22% across both portcos. The rollup didn't surface it because the lost volume was redistributed across the other six days at lower conversion. The 72-hour signal protocol caught both cases in week one of our scan.
The Revenue Recovery Lens is an AI-assisted diagnostic that runs proven recovery patterns against your own de-identified data and ranks what's recoverable — payer underpayment and denials, fee and pricing leakage, dormant relationships, coding and billing accuracy, and more. It was built across 1,000+ direct company audits, not from literature or a conference room. It runs across verticals — healthcare revenue cycle, banking and multi-location operators — in a free sample mode and a paid calibrated engagement on your data. Every figure is conservative by construction and carried through a realized-vs-estimate reconciliation, so the number that converts a pilot to a contract is the one you actually collect.
a fixed-scope fee for the 60-day diagnostic, plus 5% of revenue we recover through the engagement over the 12 months following the diagnostic, attributable to interventions named in the report. The share is negotiable above or below 5% — higher when we run more of the implementation, lower on diagnostic-only engagements. Aligned incentives: we only fully win when you do.
3× fee recovery guarantee. Available on Referral Partnership Revenue Recovery and Revenue Optimization engagements with mid-sized businesses ($30M+ revenue): if the diagnostic doesn't surface at least $500K of recoverable revenue, the flat fee is refunded in full. Diligence-friendly invoice. Mutual NDA before any data exchange. Engagement letter specifies attribution methodology line by line so there is no dispute later.
McKinsey's Provider Revenue Excellence serves 500+ physician systems with $1.8M–$5M engagements over 6–12 months. Bain Healthcare and A&M operate at similar scale. The output is a strategy deck handed back to your team for implementation.
Innovation Park serves 1–40 location operators and PE portcos under $250M EBITDA. The diagnostic is $15K–$25K and 60 days. The output is a board-ready PDF, a 90-minute presentation, a dormancy map, and a sequenced reactivation list — with an optional integration retainer if you want the methodology running as an always-on system.
If your portco has more than 50 locations and $250M+ EBITDA, you are McKinsey's customer. If it doesn't, you are ours.
PE Operating Partners with healthcare portfolios of 1–40 locations across home care, hospice, DSO, senior living, or medspa — particularly when one or more portcos has a flat or declining referral line that can't be explained in time for the next board cycle.
Mid-size operators ($5M–$150M revenue) with underperforming partnership or referral revenue, especially multi-location businesses where some sites are crushing it and some are dead. SaaS companies with partner programs that produce material ARR but no defensible attribution also fit.
We also serve non-EU companies — particularly Canadian, US, and Singaporean — entering Europe through Belgium, where Julia's institutional relationships open doors that don't open to outbound.
The diagnostic outputs a board-ready PDF designed for sponsor review: dormancy concentration map by location, top-15 reactivation priorities with estimated recovery value per relationship, location variance analysis, and a 90-day implementation roadmap. Methodology is described to diligence standard. Numbers tie to the underlying dataset row-by-row. No projections beyond what the data supports.
We will tell you on the qualification call before you commit. We have audited 200+ businesses across the relevant verticals. We have never seen one without at least one of the five recurring leakage patterns — but we have seen plenty where the recoverable number is below the cost of the next-step retainer. If the recoverable line doesn't justify continued work, we say so explicitly in the 90-minute presentation, and we don't pitch the integration retainer.
For Referral Partnership Revenue Recovery and Revenue Optimization engagements with mid-sized businesses ($30M+ revenue), the 3× fee recovery guarantee backstops this: if the diagnostic doesn't surface that much recoverable revenue, the flat fee is refunded.
Yes. Most of our diagnostic work runs on de-identified referral, partner, and pipeline data — we do not require access to patient records for the core scan. For engagements where PHI is in scope, we sign a Business Associate Agreement (BAA) before any data exchange. The engagement letter specifies data scope, retention period, and deletion timeline line by line. The diagnostic tool itself parses data on-device by default; data does not leave your environment for the standard CSV-export flow.
HIPAA Privacy and Security Rules, the Anti-Kickback Statute, Stark Law, and the False Claims Act are referenced in every healthcare engagement's compliance review. We do not give legal advice — we surface compliance risk and recommend specific counsel where needed.
Those are tools. Revenue Lens is a methodology that produces governance the tool can't produce on its own. The most common pattern we find inside post-acquisition SaaS is a partner program running on Crossbeam or PartnerStack that produces real revenue — but with attribution that drifts because nobody enforces the partner-influenced vs partner-sourced distinction. The tool gives you a dashboard. We give you the policy, the triangulation rules, and the monthly cadence that makes the partner-revenue line defensible in a board meeting.
Tooling is downstream of the methodology — never the reverse. If you already have Crossbeam, the diagnostic will tell you what the tool can't see and what governance is missing. We don't replace the tool.
FAGG/FAMHP (the Belgian Federal Agency for Medicines and Health Products) publishes the median approval timeline for clinical trial applications under the EU Clinical Trials Regulation (CTR 536/2014). For Belgium, the median is 18 days for Part I (scientific assessment) and up to 26 days for the full Part I + Part II review for early-phase trials. The EU average across member states under the same regulation is 60+ days. This is the basis on which medtech and biotech companies routing through Belgium see faster first-patient-in than equivalent filings in France, Germany, or the Netherlands. The institutional sequence we run (VLAIO → imec → KU Leuven LRD → UZ Leuven) capitalises on that timeline.
Innovation Park was founded by Julia Vorontsova, who is based in Antwerp, Belgium. Tyler Opsahl joined as COO and Healthcare Revenue Intelligence Strategist, leading the Revenue Lens methodology from Denver, USA. Together they operate the firm as a two-principal practice with no junior consultants — every engagement is delivered personally by one or both of them, with AI doing network mapping in the background.
Alvarez & Marsal Healthcare: A&M's practitioner DNA is genuinely close to ours, and their performance-improvement practice is the most credible Big-Four competitor. They operate at $800K–$2.5M engagement size with multi-month embeds. We sit below their economic floor at $15K–$25K flat + a recovery share, and we deliver in 60 days. For sub-$50M operators and single-portco diagnostics, the engagement economics favor us. For complex turnaround and CFO-level finance work, A&M is the right answer.
Accordion: PE-native, monthly retainer model, $200K–$1.2M typical. Their finance/FP&A practice is strong; their revenue practice is junior. For revenue-side partnership diagnostics specifically — especially healthcare — we are the deeper bench. For finance transformation across a portfolio, Accordion has the staffing model and the PE relationships.
Patterns from 1,000+ company audits, every week. Healthcare partnership revenue, EU institutional access, AI revenue systems. Read by PE operating partners, healthcare operators, and medtech founders. No pitch.